Gray Matter Abnormalities in Schizophrenia Patients with Tardive Dyskinesia: A Magnetic Resonance Imaging Voxel-Based Morphometry Study

PLoS ONE

Volumn 8, Issue 8, 2013, Pages

  Li, Cheng Ta ^a,b   Chou, Kun Hsien ^a   Su, Tung Ping ^a,b   Huang, Chu Chung ^a   Chen, Mu Hong ^b   Bai, Ya Mei ^a,b   Lin, Ching Po ^a  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ABNORMAL INVOLUNTARY MOVEMENT SCALE; ADULT; ARTICLE; BRAIN DISEASE; BRAIN SIZE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; CROSS-SECTIONAL STUDY; DISEASE SEVERITY; FEMALE; GRAY MATTER; GRAY MATTER ABNORMALITY; HUMAN; INFERIOR FRONTAL GYRUS; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITIVE AND NEGATIVE SYNDROME SCALE; RATING SCALE; SCHIZOPHRENIA; SIMPSON ANGUS SCALE; SUPERIOR FRONTAL GYRUS; TARDIVE DYSKINESIA; VOXEL BASED MORPHOMETRY;

ADULT; BRAIN; BRAIN MAPPING; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MOVEMENT DISORDERS; RISK FACTORS; SCHIZOPHRENIA;

EID: 84881600602     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0071034     Document Type: Article

References (68)

1. Miller DD, McEvoy JP, Davis SM, Caroff SN, Saltz BL, et al. (2005) Clinical correlates of tardive dyskinesia in schizophrenia: baseline data from the CATIE schizophrenia trial. SchizophrRes 80: 33-43.
2. Gupta S, Frank B, Madhusoodanan S, (2002) Tardive dyskinesia: legal issues and consent. Psychiatr Ann 32: 245-248.
3. Slovenko R, (2000) Update on legal issues associated with tardive dyskinesia. J Clin Psychiatry 61Suppl 4: 45-57.
4. Bai YM, Yu SC, Chen JY, Lin CY, Chou P, et al. (2005) Risperidone for pre-existing severe tardive dyskinesia: a 48-week prospective follow-up study. Int Clin Psychopharmacol 20: 79-85.
5. Bai YM, Yu SC, Lin CC, (2003) Risperidone for severe tardive dyskinesia: a 12-week randomized, double-blind, placebo-controlled study. J Clin Psychiatry 64: 1342-1348.
6. Correll CU, Schenk EM, (2008) Tardive dyskinesia and new antipsychotics. CurrOpinPsychiatry 21: 151-156.
7. Pena MS, Yaltho TC, Jankovic J, (2011) Tardive dyskinesia and other movement disorders secondary to aripiprazole. Mov Disord 26: 147-152.
8. Woods SW, Morgenstern H, Saksa JR, Walsh BC, Sullivan MC, et al. (2010) Incidence of tardive dyskinesia with atypical versus conventional antipsychotic medications: a prospective cohort study. J Clin Psychiatry 71: 463-474.
9. Chouinard G, (2006) Interrelations between psychiatric symptoms and drug-induced movement disorder. JPsychiatry Neurosci 31: 177-180.
10. Bartzokis G, Garber HJ, Marder SR, Olendorf WH, (1990) MRI in tardive dyskinesia: shortened left caudate T2. BiolPsychiatry 28: 1027-1036.
11. Granholm E, Bartzokis G, Asarnow RF, Marder SR, (1993) Preliminary associations between motor procedural learning, basal ganglia T2 relaxation times, and tardive dyskinesia in schizophrenia. Psychiatry Res 50: 33-44.
12. Mion CC, Andreasen NC, Arndt S, Swayze VW, Cohen GA, (1991) MRI abnormalities in tardive dyskinesia. Psychiatry Res 40: 157-166.
13. Elkashef AM, Buchanan RW, Gellad F, Munson RC, Breier A, (1994) Basal ganglia pathology in schizophrenia and tardive dyskinesia: an MRI quantitative study. AmJPsychiatry 151: 752-755.
14. Buckley P, O'Callaghan E, Mulvany F, Larkin C, Stack JP, et al. (1995) Basal ganglia T2 relaxation times in schizophrenia: a quantitative magnetic resonance imaging study in relation to tardive dyskinesia. Psychiatry Res 61: 95-102.
15. Harvey I, Ron MA, Murray R, Lewis S, Barker G, et al. (1991) MRI in schizophrenia: basal ganglia and white matter T1 times. PsycholMed 21: 587-598.
16. Waddington JL, O'Callaghan E, Buckley P, Madigan C, Redmond O, et al. (1995) Tardive dyskinesia in schizophrenia. Relationship to minor physical anomalies, frontal lobe dysfunction and cerebral structure on magnetic resonance imaging. BrJPsychiatry 167: 41-44.
17. Sachdev P, Hume F, Toohey P, Doutney C, (1996) Negative symptoms, cognitive dysfunction, tardive akathisia and tardive dyskinesia. Acta Psychiatr Scand 93: 451-459.
18. Telfer S, Shivashankar S, Krishnadas R, McCreadie RG, Kirkpatrick B, (2011) Tardive dyskinesia and deficit schizophrenia. Acta Psychiatr Scand 124: 357-362.
19. Park IH, Kim JJ, Chun J, Jung YC, Seok JH, et al. (2009) Medial prefrontal default-mode hypoactivity affecting trait physical anhedonia in schizophrenia. Psychiatry Res 171: 155-165.
20. Semkovska M, Bedard MA, Stip E, (2001) [Hypofrontality and negative symptoms in schizophrenia: synthesis of anatomic and neuropsychological knowledge and ecological perspectives]. Encephale 27: 405-415.
21. Cerasa A, Messina D, Pugliese P, Morelli M, Lanza P, et al. (2011) Increased prefrontal volume in PD with levodopa-induced dyskinesias: a voxel-based morphometry study. Mov Disord 26: 807-812.
22. Casey DE, (2004) Pathophysiology of antipsychotic drug-induced movement disorders. J Clin Psychiatry 65Suppl 9: 25-28.
23. Schooler NR, Kane JM (1982) Research diagnoses for tardive dyskinesia. ArchGenPsychiatry 39: 486-487.
24. Lai IC, Mo GH, Chen ML, Wang YC, Chen JY, et al. (2011) Analysis of genetic variations in the dopamine D1 receptor (DRD1) gene and antipsychotics-induced tardive dyskinesia in schizophrenia. Eur J Clin Pharmacol 67: 383-388.
25. Lai IC, Chen ML, Wang YC, Chen JY, Liao DL, et al. (2011) Analysis of genetic variations in the human melatonin receptor (MTNR1A, MTNR1B) genes and antipsychotics-induced tardive dyskinesia in schizophrenia. World J Biol Psychiatry 12: 143-148.
26. Bai YM, Chou KH, Lin CP, Chen IY, Li CT, et al. (2009) White matter abnormalities in schizophrenia patients with tardive dyskinesia: a diffusion tensor image study. Schizophr Res 109: 167-181.
27. Chen JY, Bai YM, Pyng LY, Lin CC, (2001) Risperidone for tardive dyskinesia. Am J Psychiatry 158: 1931-1932.
28. Liou YJ, Wang YC, Chen JY, Chen ML, Chen TT, et al. (2008) The coding-synonymous polymorphism rs1045280 (Ser280Ser) in beta-arrestin 2 (ARRB2) gene is associated with tardive dyskinesia in Chinese patients with schizophrenia. Eur J Neurol 15: 1406-1408.
29. Wang YC, Yang CC, Bai YM, Kuo TB, (2008) Heart rate variability in schizophrenic patients switched from typical antipsychotic agents to amisulpride and olanzapine. 3-month follow-up. Neuropsychobiology 57: 200-205.
30. Liou YJ, Chen ML, Wang YC, Chen JY, Liao DL, et al. (2009) Analysis of genetic variations in the RGS9 gene and antipsychotic-induced tardive dyskinesia in schizophrenia. Am J Med Genet B Neuropsychiatr Genet 150B: 239-242.
31. Liou YJ, Chen ML, Wang YC, Chen JY, Liao DL, et al. (2009) Analysis of genetic variations in the human Par-4 (PAWR) gene and tardive dyskinesia in schizophrenia. Am J Med Genet B Neuropsychiatr Genet 150B: 439-440.
32. Lin CC, Bai YM, Chen JY, Wang YC, Liou YJ, (2008) Treatment of clozapine-associated tardive dyskinesia. Prog Neuropsychopharmacol Biol Psychiatry 32: 599-600.
33. Mo GH, Lai IC, Wang YC, Chen JY, Lin CY, et al. (2007) Support for an association of the C939T polymorphism in the human DRD2 gene with tardive dyskinesia in schizophrenia. Schizophr Res 97: 302-304.
34. Liou YJ, Wang YC, Chen JY, Bai YM, Lin CC, et al. (2007) Association analysis of polymorphisms in the N-methyl-D-aspartate (NMDA) receptor subunit 2B (GRIN2B) gene and tardive dyskinesia in schizophrenia. Psychiatry Res 153: 271-275.
35. Liou YJ, Lai IC, Liao DL, Chen JY, Lin CC, et al. (2006) The human dopamine receptor D2 (DRD2) gene is associated with tardive dyskinesia in patients with schizophrenia. Schizophr Res 86: 323-325.
36. Liou YJ, Lai IC, Lin MW, Bai YM, Lin CC, et al. (2006) Haplotype analysis of endothelial nitric oxide synthase (NOS3) genetic variants and tardive dyskinesia in patients with schizophrenia. Pharmacogenet Genomics 16: 151-157.
37. Liou YJ, Wang YC, Lin CC, Bai YM, Lai IC, et al. (2005) Association analysis of NAD(P)Hratioquinone oxidoreductase (NQO1) Pro187Ser genetic polymorphism and tardive dyskinesia in patients with schizophrenia in Taiwan. Int J Neuropsychopharmacol 8: 483-486.
38. Liou YJ, Liao DL, Chen JY, Wang YC, Lin CC, et al. (2004) Association analysis of the dopamine D3 receptor gene ser9gly and brain-derived neurotrophic factor gene val66met polymorphisms with antipsychotic-induced persistent tardive dyskinesia and clinical expression in Chinese schizophrenic patients. Neuromolecular Med 5: 243-251.
39. Lai IC, Wang YC, Lin CC, Bai YM, Liao DL, et al. (2005) Negative association between catechol-O-methyltransferase (COMT) gene Val158Met polymorphism and persistent tardive dyskinesia in schizophrenia. J Neural Transm 112: 1107-1113.
40. Liou YJ, Wang YC, Bai YM, Lin CC, Yu SC, et al. (2004) Cytochrome P-450 2D6*10 C188T polymorphism is associated with antipsychotic-induced persistent tardive dyskinesia in Chinese schizophrenic patients. Neuropsychobiology 49: 167-173.
41. Wang YC, Liou YJ, Liao DL, Bai YM, Lin CC, et al. (2004) Association analysis of a neural nitric oxide synthase gene polymorphism and antipsychotics-induced tardive dyskinesia in Chinese schizophrenic patients. J Neural Transm 111: 623-629.
42. Lai IC, Liao DL, Bai YM, Lin CC, Yu SC, et al. (2002) Association study of the estrogen receptor polymorphisms with tardive dyskinesia in schizophrenia. Neuropsychobiology 46: 173-175.
43. Rajapakse JC, Giedd JN, Rapoport JL, (1997) Statistical approach to segmentation of single-channel cerebral MR images. IEEE Trans Med Imaging 16: 176-186.
44. Tohka J, Zijdenbos A, Evans A, (2004) Fast and robust parameter estimation for statistical partial volume models in brain MRI. Neuroimage 23: 84-97.
45. Cuadra MB, Cammoun L, Butz T, Cuisenaire O, Thiran JP, (2005) Comparison and validation of tissue modelization and statistical classification methods in T1-weighted MR brain images. IEEE Trans Med Imaging 24: 1548-1565.
46. Wang Z, Zhang Z, Jiao Q, Liao W, Chen G, et al. (2012) Impairments of thalamic nuclei in idiopathic generalized epilepsy revealed by a study combining morphological and functional connectivity MRI. PLoS One 7: e39701.
47. Li R, Qin W, Zhang Y, Jiang T, Yu C, (2012) The neuronal correlates of digits backward are revealed by voxel-based morphometry and resting-state functional connectivity analyses. PLoS One 7: e31877.
48. Tian L, Meng C, Yan H, Zhao Q, Liu Q, et al. (2011) Convergent evidence from multimodal imaging reveals amygdala abnormalities in schizophrenic patients and their first-degree relatives. PLoS One 6: e28794.
49. Liang P, Wang Z, Yang Y, Jia X, Li K, (2011) Functional disconnection and compensation in mild cognitive impairment: evidence from DLPFC connectivity using resting-state fMRI. PLoS One 6: e22153.
50. Rey M, Dellatolas G, Bancaud J, Talairach J, (1988) Hemispheric lateralization of motor and speech functions after early brain lesion: study of 73 epileptic patients with intracarotid amytal test. Neuropsychologia 26: 167-172.
51. Tenback DE, van Harten PN, Slooff CJ, van Os J, (2006) Evidence that early extrapyramidal symptoms predict later tardive dyskinesia: a prospective analysis of 10,000 patients in the European Schizophrenia Outpatient Health Outcomes (SOHO) study. AmJPsychiatry 163: 1438-1440.
52. Ascher-Svanum H, Zhu B, Faries D, Peng X, Kinon BJ, et al. (2008) Tardive Dyskinesia and the 3-Year Course of Schizophrenia: Results From a Large, Prospective, Naturalistic Study. JClinPsychiatry: e1-e9.
53. Eberhard J, Lindstrom E, Levander S, (2006) Tardive dyskinesia and antipsychotics: a 5-year longitudinal study of frequency, correlates and course. IntClinPsychopharmacol 21: 35-42.
54. Gebhardt S, Hartling F, Hanke M, Theisen FM, von Georgi R, et al. (2008) Relations between movement disorders and psychopathology under predominantly atypical antipsychotic treatment in adolescent patients with schizophrenia. EurChild AdolescPsychiatry 17: 44-53.
55. Berry K, Drake R, Stewart C, Aitkin LM, Byrne J, et al. (2007) Orofacial dyskinesia, frontal lobe dysfunction, and coping in older people with psychosis. AmJGeriatrPsychiatry 15: 800-806.
56. Tenback DE, van Harten PN, Slooff CJ, van Os J, (2007) Worsening of psychosis in schizophrenia is longitudinally associated with tardive dyskinesia in the European Schizophrenia Outpatient Health Outcomes study. ComprPsychiatry 48: 436-440.
57. Leitman DI, Wolf DH, Laukka P, Ragland JD, Valdez JN, et al. (2011) Not pitch perfect: sensory contributions to affective communication impairment in schizophrenia. Biol Psychiatry 70: 611-618.
58. Leung HC, Cai W, (2007) Common and differential ventrolateral prefrontal activity during inhibition of hand and eye movements. J Neurosci 27: 9893-9900.
59. Sarro S, Pomarol-Clotet E, Canales-Rodriguez EJ, Salvador R, Gomar JJ, et al. (2012) Structural brain changes associated with tardive dyskinesia in schizophrenia. Br J Psychiatry.
60. Simpson GM, Lee JH, Zoubok B, Gardos G, (1979) A rating scale for tardive dyskinesia. Psychopharmacology (Berl) 64: 171-179.
61. Alexander GE, Crutcher MD, (1990) Functional architecture of basal ganglia circuits: neural substrates of parallel processing. Trends Neurosci 13: 266-271.
62. Goldman-Rakic PS, Lidow MS, Smiley JF, Williams MS (1992) The anatomy of dopamine in monkey and human prefrontal cortex. J Neural Transm Suppl 36: 163-177.
63. Schultz W, Tremblay L, Hollerman JR, (2000) Reward processing in primate orbitofrontal cortex and basal ganglia. CerebCortex 10: 272-284.
64. Bengtsson SL, Ehrsson HH, Forssberg H, Ullen F, (2004) Dissociating brain regions controlling the temporal and ordinal structure of learned movement sequences. Eur J Neurosci 19: 2591-2602.
65. Aron AR, Fletcher PC, Bullmore ET, Sahakian BJ, Robbins TW, (2003) Stop-signal inhibition disrupted by damage to right inferior frontal gyrus in humans. Nat Neurosci 6: 115-116.
66. Zhang XY, Tan YL, Zhou DF, Cao LY, Wu GY, et al. (2007) Disrupted antioxidant enzyme activity and elevated lipid peroxidation products in schizophrenic patients with tardive dyskinesia. JClinPsychiatry 68: 754-760.
67. Lerner V, Miodownik C, Kaptsan A, Bersudsky Y, Libov I, et al. (2007) Vitamin B6 treatment for tardive dyskinesia: a randomized, double-blind, placebo-controlled, crossover study. JClinPsychiatry 68: 1648-1654.
68. Libov I, Miodownik C, Bersudsky Y, Dwolatzky T, Lerner V, (2007) Efficacy of piracetam in the treatment of tardive dyskinesia in schizophrenic patients: a randomized, double-blind, placebo-controlled crossover study. JClinPsychiatry 68: 1031-1037.